Find Suzetrigine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

0

CEP/COS

0

JDMF

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2649467-58-1, 2-pyridinecarboxamide, 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-, Suzetrigine [inn], Log73m21h5, Schembl23462160, Gtpl12630
Molecular Formula
C21H20F5N3O4
Molecular Weight
473.4  g/mol
InChI Key
XSQUJFKRXZMOKA-PAFIKIDNSA-N
FDA UNII
LOG73M21H5

Suzetrigine
1 2D Structure

Suzetrigine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide
2.1.2 InChI
InChI=1S/C21H20F5N3O4/c1-9-14(11-4-5-12(22)15(23)16(11)32-3)17(33-20(9,2)21(24,25)26)19(31)29-10-6-7-28-13(8-10)18(27)30/h4-9,14,17H,1-3H3,(H2,27,30)(H,28,29,31)/t9-,14-,17+,20+/m0/s1
2.1.3 InChI Key
XSQUJFKRXZMOKA-PAFIKIDNSA-N
2.1.4 Canonical SMILES
CC1C(C(OC1(C)C(F)(F)F)C(=O)NC2=CC(=NC=C2)C(=O)N)C3=C(C(=C(C=C3)F)F)OC
2.1.5 Isomeric SMILES
C[C@H]1[C@H]([C@@H](O[C@@]1(C)C(F)(F)F)C(=O)NC2=CC(=NC=C2)C(=O)N)C3=C(C(=C(C=C3)F)F)OC
2.2 Other Identifiers
2.2.1 UNII
LOG73M21H5
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2649467-58-1

2. 2-pyridinecarboxamide, 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-

3. Suzetrigine [inn]

4. Log73m21h5

5. Schembl23462160

6. Gtpl12630

7. Vx548

8. Ex-a7354

9. Vx-548

10. Compound 7 [wo2021113627a1]

11. Hy-148800

12. Cs-0641183

13. 4-[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- Dimethyl-5-(trifluoromethyl)oxolane-2- Carboxamido]pyridine-2-carboxamide

14. 4-[[(2r, 3s, 4s, 5r)-3-(3, 4-difluoro-2-methoxyphenyl)-4, 5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide

15. 4-[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide

16. 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-2-pyridinecarboxamide

2.4 Create Date
2021-08-21
3 Chemical and Physical Properties
Molecular Weight 473.4 g/mol
Molecular Formula C21H20F5N3O4
XLogP33
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count5
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area104
Heavy Atom Count33
Formal Charge0
Complexity741
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1752690600,"product":"SUZETRIGINE HPMC-AS (EXPORT INVOICE NO: 6125010201 DT : 14.07.2025)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"SHAHJALAL ISLAMI BANK LTD","customerCountry":"BANGLADESH","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"15000","totalValueFC":"3621.7","currency":"USD","unitRateINR":1246812,"date":"17-Jul-2025","totalValueINR":"311703","totalValueInUsd":"3621.7","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"3637183","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1762713000,"product":"SUZETRIGINE ASD (EXPORT INVOICE NO : 6125010473 DT : 31.10.2025)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"EVA PHARMA FOR PHARMACEUTICAL INDUS","customerCountry":"EGYPT","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"16500","totalValueFC":"48686.1","currency":"USD","unitRateINR":1442423,"date":"10-Nov-2025","totalValueINR":"4327269","totalValueInUsd":"48686.1","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"5502614","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1762713000,"product":"SUZETRIGINE ASD (EXPORT INVOICE NO :6125010468 DT : 31.10.2025)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"NATIONAL CREDIT AND COMMERCE","customerCountry":"BANGLADESH","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"5000","totalValueFC":"4881.2","currency":"USD","unitRateINR":433850,"date":"10-Nov-2025","totalValueINR":"433850","totalValueInUsd":"4881.2","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"14276371","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2026","qtr":"Q1","strtotime":1768847400,"product":"SUZETRIGINE (IN-HOUSE) (EXPORT INVOICE NO.: 6125010593 DATE : 27.12.2025)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"INTERPHARM FOR IMPORT, EXPORT &","customerCountry":"EGYPT","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"20000","totalValueFC":"1926.1","currency":"USD","unitRateINR":1747660,"date":"20-Jan-2026","totalValueINR":"174766","totalValueInUsd":"1926.1","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"1.7976931348623157e308","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2026","qtr":"Q1","strtotime":1769106600,"product":"SUZETRIGINE ASD (EXPORT INVOICE NO: 6125010635 DT: 06.01.2026)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"DBL PHARMACEUTICALS LTD.,","customerCountry":"BANGLADESH","quantity":"0.60","actualQuantity":"0.6","unit":"KGS","unitRateFc":"5000","totalValueFC":"2905.7","currency":"N\/A","unitRateINR":439416.66666666669,"date":"23-Jan-2026","totalValueINR":"263650","totalValueInUsd":"2905.7","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"0","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1754073000,"product":"SUZETRIGINE- 4-[[(2R,3S,4S,5R)-3-(3,4- DIFLUORO-2-METHOXYPHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL)OXOLANE -2-CARBONYL]AMI4-[[(2R,3S,4S,5R)-3-(3,4- DIFLUORO-2-METHOXYPHENYL)-4,5-DIME","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"INFOARK INTERNATIONAL COLIMITED","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"ALEMBIC PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"25000","totalValueFC":"7438.3","currency":"USD","unitRateINR":"2170000","date":"02-Aug-2025","totalValueINR":"651000","totalValueInUsd":"7438.3","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"3651700","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"ROOM 807B NEW LAND PLAZA, 58 FUCHENG ROAD HAIDIAN DISTRICT, BEIJING CHINA","customerAddress":"ALEMBIC ROAD"}]
17-Jul-2025
23-Jan-2026
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
Top news of 2025: Drugmakers invest in US capacities, agree to lower Medicaid prices; Pfizer buys obesity-focused biotech Metsera
The year 2025 was an eventful one, marked by increased trade tensions, tariff threats, accelerated adoption of artificial intelligence (AI) in drug development, and an intensified race for next-gen obesity treatments. Major drugmakers pledged substantial investments in the US to mitigate potential tariffs. By the year-end, the Trump Administration announced deals with several drugmakers to lower prices for its Medicaid program and for cash payers.The year also saw significant changes at the US Food and Drug Administration (FDA), including high-profile leadership changes and workforce reductions. The agency rolled out advanced AI systems — known as agentic AI — to help its staff achieve specific goals.Several large mergers and acquisitions also shaped 2025. Pfizer bought obesity-focused biopharma Metsera for US$ 10 billion and Johnson & Johnson acquired Intra-Cellular for US$ 14.6 billion. Vertex Pharmaceuticals introduced a new, non-opioid painkiller, Journavx (suzetrigine), and GSK launched Blujepa (gepotidacin) which is now approved for treating uncomplicated urinary tract infections (uUTIs) and gonorrhea. Here are the top stories that made it to PharmaCompass’ top 10 Phispers of 2025.I. Drugmakers pledge over US$ 370 bn in building US capacities; lower Medicaid prices From the outset, 2025 was defined by tariff threats and trade tensions as the US government signaled potential steep tariffs on imported branded drugs. To mitigate the impact of potential tariffs, multinational drugmakers announced sizable investments in the US.Eli Lilly has announced a US$ 27 billion investment, followed by Johnson & Johnson (US$ 55 billion), Novartis (US$ 23 billion), Roche (US$ 50 billion), Bristol Myers Squibb (US$ 40 billion), AstraZeneca (US$ 50 billion), and GSK (US$ 30 billion). A Wall Street Journal report dated September 16 states that drugmakers have pledged more than US$ 370 billion in US investments due to tariff threats, while ThinkGlobalHealth estimates this number at over US$ 480 billion.On September 30, Pfizer struck a US$ 70 billion deal with the US government to lower Medicaid drug prices and expand domestic manufacturing. And in December, US President Donald Trump and nine major drugmakers announced agreements to lower medicine prices for the government’s Medicaid program and for cash payers. These prices will be in line with the lowest prices paid by other developed nations (known as the ‘most-favored-nation’ pricing).II.  Pfizer doubles down on obesity market, buys Metsera for US$ 10 bn, inks deal with YaoPharmaPfizer aggressively pursued the booming obesity market. In November, Pfizer completed the US$ 10 billion (approximately) acquisition of Metsera, a clinical-stage biopharma focused on drugs for obesity and cardiometabolic diseases, after winning a bidding war against Novo Nordisk. The following month, Pfizer signed a deal worth up to US$ 2.1 billion with China’s YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to develop and commercialize an experimental GLP-1 weight-loss drug — YP05002.III.  FDA approves Vertex’s non-opioid painkiller that blocks acute pain at sourceFDA approved Vertex Pharmaceuticals’ non-opioid painkiller, Journavx (suzetrigine), for the treatment of moderate-to-severe acute pain in adults. This represents the first new class of pain medication in over two decades, and offers an alternative to opioid analgesics.IV. GSK’s Blujepa approved for treating uncomplicated UTIs; also okayed for gonorrheaIn March 2025, FDA approved GSK’s antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (uUTIs) in female patients aged 12 years and older who weigh at least 40 kg. This marked the first approval of a new class of        for uUTIs in nearly 30 years. In December, FDA expanded Blujepa’s label to include treatment for gonorrhea, a sexually transmitted disease.V. J&J acquires neuroscience biotech Intra-Cellular for US$ 14.6 billionJohnson & Johnson kicked off 2025 with the US$ 14.6 billion acquisition of Intra-Cellular Therapies, strengthening its neuroscience portfolio. Intra-Cellular’s Caplyta (lumateperone) is a once-daily oral therapy approved for treating adults with schizophrenia and depressive episodes associated with bipolar I or II disorder.VI. Changes at FDA: A year marked by high-profile resignations, rollout of agentic AIFDA experienced significant organizational changes in 2025, including senior leadership departures, amid the Trump administration’s policy shifts. Approximately 3,500 FDA staff were slated for layoffs beginning in April, raising concerns about the agency's review systems. Health and Human Services (HHS) secretary Robert F Kennedy Jr’s anti-vaccine stance led to internal tensions, controversies and departures of senior vaccine officials.The agency is transforming itself  — in December, it announced the deployment of agentic AI capabilities for all its employees. Agentic AI refers to advanced AI systems designed to achieve specific goals by planning, reasoning, and executing multi-step actions.VII. Sanofi-Alnylam’s Qfitlia becomes first approved RNAi med for hemophilia A, BFDA approved Qfitlia (fitusiran) — the first RNA interface (RNAi) therapeutic for treating rare bleeding disorders hemophilia A and B. Developed through a collaboration between Sanofi and Alnylam Pharmaceuticals, Qfitlia is indicated for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia patients aged 12 and older.VIII. Astra-Daiichi Sankyo’s Datroway bags FDA nod for treating advanced lung, breast cancerAstraZeneca and Daiichi Sankyo’s precision drug Datroway (datopotamab deruxtecan) won two key approvals in 2025. In January, Datroway received FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. And in June, it bagged accelerated approval for the treatment of an advanced form of non-small cell lung cancer in adults who had received prior treatment.IX. Novartis continues to forge deals; inks US$ 12 bn deal with Avidity, US$ 2 bn deal with Arrowhead Following active deal-making in 2024, Novartis continued to make strategic acquisitions in 2025. It acquired US-based Avidity Biosciences for approximately US$ 12 billion to expand its rare muscle disorders portfolio. As part of the deal, Avidity will spin off its early-stage cardiology drug programs into a new publicly-traded company called SpinCo.Novartis also signed a licensing and options deal with China-based Argo Biopharmaceuticals worth up to US$ 5.2 billion for experimental cardiovascular drug candidates, and a US$ 2 billion licensing and collaboration agreement with Arrowhead Pharmaceuticals for its preclinical neurodegenerative disease candidate. Novartis also agreed to buy Anthos Therapeutics, a drug development company majority-owned by investment firm Blackstone, for up to US$ 3.1 billion.X. Merck acquires Verona for US$ 10 billion; inks US$ 9.2 billion deal to buy CidaraMerck acquired London‑based Verona Pharma for approximately US$ 10 billion as part of its strategy to diversify ahead of the 2028 patent expiration of its cancer blockbuster, Keytruda (pembrolizumab). Merck also agreed to acquire Cidara Therapeutics in a deal valued at approximately US$ 9.2 billion, strengthening its infectious disease portfolio.  

Impressions: 3952

https://www.pharmacompass.com/radio-compass-blog/top-news-of-2025-drugmakers-invest-in-us-capacities-agree-to-lower-medicaid-prices-pfizer-buys-obesity-focused-biotech-metsera

#Phispers by PHARMACOMPASS
01 Jan 2026

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 2649467-58-1 / Suzetrigine API manufacturers, exporters & distributors?

Suzetrigine manufacturers, exporters & distributors 1

29

PharmaCompass offers a list of Suzetrigine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Suzetrigine manufacturer or Suzetrigine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Suzetrigine manufacturer or Suzetrigine supplier.

PharmaCompass also assists you with knowing the Suzetrigine API Price utilized in the formulation of products. Suzetrigine API Price is not always fixed or binding as the Suzetrigine Price is obtained through a variety of data sources. The Suzetrigine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Suzetrigine

Synonyms

2649467-58-1, 2-pyridinecarboxamide, 4-[[[(2r,3s,4s,5r)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-, Suzetrigine [inn], Log73m21h5, Schembl23462160, Gtpl12630

Cas Number

2649467-58-1

Unique Ingredient Identifier (UNII)

LOG73M21H5

Suzetrigine Manufacturers

A Suzetrigine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Suzetrigine, including repackagers and relabelers. The FDA regulates Suzetrigine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Suzetrigine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Suzetrigine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Suzetrigine Suppliers

A Suzetrigine supplier is an individual or a company that provides Suzetrigine active pharmaceutical ingredient (API) or Suzetrigine finished formulations upon request. The Suzetrigine suppliers may include Suzetrigine API manufacturers, exporters, distributors and traders.

click here to find a list of Suzetrigine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Suzetrigine WC

A Suzetrigine written confirmation (Suzetrigine WC) is an official document issued by a regulatory agency to a Suzetrigine manufacturer, verifying that the manufacturing facility of a Suzetrigine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Suzetrigine APIs or Suzetrigine finished pharmaceutical products to another nation, regulatory agencies frequently require a Suzetrigine WC (written confirmation) as part of the regulatory process.

click here to find a list of Suzetrigine suppliers with Written Confirmation (WC) on PharmaCompass.

Suzetrigine NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Suzetrigine as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Suzetrigine API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Suzetrigine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Suzetrigine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Suzetrigine NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Suzetrigine suppliers with NDC on PharmaCompass.

Suzetrigine GMP

Suzetrigine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Suzetrigine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Suzetrigine GMP manufacturer or Suzetrigine GMP API supplier for your needs.

Suzetrigine CoA

A Suzetrigine CoA (Certificate of Analysis) is a formal document that attests to Suzetrigine's compliance with Suzetrigine specifications and serves as a tool for batch-level quality control.

Suzetrigine CoA mostly includes findings from lab analyses of a specific batch. For each Suzetrigine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Suzetrigine may be tested according to a variety of international standards, such as European Pharmacopoeia (Suzetrigine EP), Suzetrigine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Suzetrigine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty